World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
22564
World Ranking
17150
National Ranking
8594

Jack W. Singer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jack W. Singer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 250 publications — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jack W. Singer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jack W. Singer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Jack W. Singer spends much of his time researching Internal medicine, Surgery, Immunology, Bone marrow and Gastroenterology. His Internal medicine research incorporates themes from Endocrinology and Oncology. His work in Immunology covers topics such as Stem cell which are related to areas like Molecular biology and Clone.

His Bone marrow study integrates concerns from other disciplines, such as Recombinant DNA, Microgram, Complication, Granulocyte macrophage colony-stimulating factor and Acute lymphocytic leukemia. His research in Gastroenterology intersects with topics in Methotrexate, Cyclophosphamide, Chemotherapy, Transplantation and Immunotherapy. His biological study spans a wide range of topics, including Clinical trial and Absolute neutrophil count.

His most cited work include:

  • Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. (1755 citations)
  • One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. (789 citations)
  • Mechanisms of action of arsenic trioxide. (778 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Immunology, Surgery, Bone marrow and Haematopoiesis. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology. The concepts of his Immunology study are interwoven with issues in Progenitor cell, Stem cell and Molecular biology.

His work on Transplantation, Chemotherapy and Regimen as part of general Surgery study is frequently linked to Placebo, bridging the gap between disciplines. His Bone marrow research includes elements of Acute lymphocytic leukemia and Granulocyte macrophage colony-stimulating factor. His work carried out in the field of Haematopoiesis brings together such families of science as Cell, Peripheral blood mononuclear cell, Philadelphia chromosome and Pathology.

He most often published in these fields:

  • Internal medicine (34.16%)
  • Immunology (38.27%)
  • Surgery (23.46%)

What were the highlights of his more recent work (between 2009-2020)?

  • Internal medicine (34.16%)
  • Pacritinib (7.00%)
  • Pharmacology (11.52%)

In recent papers he was focusing on the following fields of study:

His main research concerns Internal medicine, Pacritinib, Pharmacology, Surgery and Pixantrone. His work deals with themes such as Gastroenterology and Oncology, which intersect with Internal medicine. In his study, CHOP, Ejection fraction, Vincristine, Mantle cell lymphoma and Cyclophosphamide is strongly linked to Diffuse large B-cell lymphoma, which falls under the umbrella field of Gastroenterology.

His study in Pacritinib is interdisciplinary in nature, drawing from both Cancer research, Janus kinase 2 and Immune system. His Pharmacology research is multidisciplinary, incorporating perspectives in Cancer cell, Paclitaxel, Paclitaxel Poliglumex and Erlotinib. In his study, which falls under the umbrella issue of Pixantrone, International Prognostic Index, Ifosfamide and Progressive disease is strongly linked to Aggressive Non-Hodgkin Lymphoma.

Between 2009 and 2020, his most popular works were:

  • Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial (91 citations)
  • Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. (81 citations)
  • Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial (78 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His primary areas of study are Internal medicine, Pacritinib, Surgery, Pixantrone and Myelofibrosis. His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology. His studies examine the connections between Gastroenterology and genetics, as well as such issues in Diffuse large B-cell lymphoma, with regards to Pharmacology.

His Pacritinib study incorporates themes from Cancer research and Janus kinase 2. Jack W. Singer has researched Surgery in several fields, including Rituximab, Lymphoma and Oncology. His research on Myelofibrosis also deals with topics like

  • Randomized controlled trial together with Ruxolitinib,
  • Clinical endpoint together with Nausea and Cytopenia,
  • Adverse effect, which have a strong connection to Neutropenia.

Best Publications

  • Mechanisms of action of arsenic trioxide.

    Wilson H. Miller;Hyman M. Schipper;Janet S. Lee;Jack Singer

  • One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

    ED Thomas;CD Buckner;M Banaji;RA Clift

  • Marrow transplantation for acute nonlymphoblastic leukemia in first remission.

    Thomas Ed;Buckner Cd;Clift Ra;Fefer A

  • Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia

    E D Thomas;R A Clift;A Fefer;F R Appelbaum

  • Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties.

    R G Andrews;J W Singer;I D Bernstein

  • Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

    John Nemunaitis;John Nemunaitis;John Nemunaitis;Susan N. Rabinowe;Jack W. Singer;Jack W. Singer;Jack W. Singer;Philip J. Bierman

  • Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors

    Robert G. Andrews;Jack W. Singer;Irwin D. Bernstein

  • Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.

    R Storb;R L Prentice;C D Buckner;R A Clift

  • Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor

    W Bensinger;J Singer;F Appelbaum;K Lilleby

  • Graft-versus-Host Disease as Adoptive Immunotherapy in Patients with Advanced Hematologic Neoplasms

    K M Sullivan;R Storb;C D Buckner;A Fefer

  • Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia

    Philip J. Fialkow;Jack W. Singer;Wendy H. Raskind;John W. Adamson

  • Evidence for a Multistep Pathogenesis of a Myelodysplastic Syndrome

    Wendy H. Raskind;Wendy H. Raskind;Nagendra Tirumali;Nagendra Tirumali;Robert Jacobson;Robert Jacobson;Jack Singer;Jack Singer

  • Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration

    James B. Konopka;Susan M. Watanabe;Jack W. Singer;Steven J. Collins

  • Acute nonlymphocytic leukemia: heterogeneity of stem cell origin.

    Philip J. Fialkow;Jack W. Singer;John W. Adamson;Kalpana Vaidya

  • Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

    J Nemunaitis;JW Singer;CD Buckner;R Hill

  • Marrow Transplantation in Thirty Untransfused Patients with Severe Aplastic Anemia

    Storb R;Thomas Ed;Buckner Cd;Clift Ra

  • Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

    John Mascarenhas;Ronald Hoffman;Moshe Talpaz;Aaron T. Gerds

  • Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.

    Jack W. Singer

  • Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

    Ruben A. Mesa;Alessandro M. Vannucchi;Adam Mead;Miklos Egyed

  • Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

    Corey J. Langer;Kenneth J. O’Byrne;Mark A. Socinski;Sergei M. Mikhailov

Frequent Co-Authors

E. Donnall Thomas
E. Donnall Thomas University of Washington
Jean E. Sanders
Jean E. Sanders Fred Hutchinson Cancer Research Center
John W. Adamson
John W. Adamson University of California, San Diego
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Kristine Doney
Kristine Doney Fred Hutchinson Cancer Research Center
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
John Nemunaitis
John Nemunaitis Gradalis (United States)
Wendy H. Raskind
Wendy H. Raskind University of Washington
Buckner Cd
Buckner Cd National Cancer Institute
William I. Bensinger
William I. Bensinger Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in healthcare doesn’t always mean becoming a doctor. There are flexible, rewarding options in nursing, administration, and beyond. Many students opt for direct entry msn programs online, which allow non-nurses to swiftly transition into advanced nursing roles, often through accelerated online study.

If you’re looking for more accessible entry points, several direct admit nursing programs offer streamlined admissions for first-time students, with some schools removing exam barriers. This is reinforced by the rising number of accredited programs where do all nursing schools require the teas is a common question—fortunately, many do not, offering more accessible pathways.

Medical administration roles are also in demand. Pursuing certification through one of the medical billing and coding financial aid programs can lead to stable careers, especially for those seeking flexible or remote work. All these pathways provide vital support to the healthcare system, while also offering strong job opportunities for students who may want alternatives to traditional medical school.

Best Scientists Citing Jack W. Singer

Trending Scientists

Recently Published Articles